Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.
Healthcare consultant Jared Wolff is joined by Bruna Favetta who has experience with the development of patent strategy, and Kate Jones who has a background in law.
AMARIN has recently found themselves in unchartered territory as VASCEPA’s drug patent is being challenged by generic producers, this episode explores:
- Why this case of VASCEPA is significant
- How this may set a future precedent in drug patent law
Thanks for listening!
05/07/20 • 11 min
Episode Comments
0.0
out of 5
No ratings yet
eg., What part of this podcast did you like? Ask a question to the host or other listeners...
Post
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/cbpartners-pharma-take-away-89749/amarins-vascepa-patent-loss-is-it-obviousness-4866933"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to amarin's vascepa patent loss: is it obvious(ness)? on goodpods" style="width: 225px" /> </a>
Copy